
Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) – Research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Corcept Therapeutics in a research note issued to investors on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of $2.05 for the year, down from their previous estimate of $2.15. HC Wainwright has a “Buy” rating and a $165.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.97 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.98 EPS, Q2 2027 earnings at $0.80 EPS, Q3 2027 earnings at $0.94 EPS, Q4 2027 earnings at $1.05 EPS, FY2027 earnings at $3.39 EPS, FY2028 earnings at $6.76 EPS, FY2029 earnings at $9.58 EPS and FY2030 earnings at $12.92 EPS.
Several other research analysts have also weighed in on the company. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a report on Monday, July 27th. Zacks Research downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Finally, Piper Sandler restated an “overweight” rating and issued a $173.00 price target (up from $165.00) on shares of Corcept Therapeutics in a report on Wednesday. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $139.50.
Corcept Therapeutics Trading Up 1.6%
Corcept Therapeutics stock opened at $72.77 on Friday. The stock has a fifty day moving average price of $107.58 and a 200 day moving average price of $75.65. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $126.38. The firm has a market capitalization of $7.96 billion, a P/E ratio of 57.30 and a beta of 0.54.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.17. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. The company had revenue of $340.47 million during the quarter, compared to analysts’ expectations of $339.12 million. During the same period in the previous year, the firm posted $0.16 earnings per share. The business’s revenue for the quarter was up 64.0% compared to the same quarter last year.
Insider Buying and Selling at Corcept Therapeutics
In related news, Director Kimberly Park sold 26,685 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $122.55, for a total transaction of $3,270,246.75. Following the completion of the sale, the director directly owned 30,000 shares of the company’s stock, valued at approximately $3,676,500. This represents a 47.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Roberto Vieira sold 58,333 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $110.76, for a total value of $6,460,963.08. Following the transaction, the insider owned 4,242 shares in the company, valued at approximately $469,843.92. This represents a 93.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 382,536 shares of company stock worth $43,406,554. Corporate insiders own 20.70% of the company’s stock.
Hedge Funds Weigh In On Corcept Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Allworth Financial LP boosted its holdings in Corcept Therapeutics by 3.8% in the third quarter. Allworth Financial LP now owns 4,039 shares of the biotechnology company’s stock worth $465,000 after purchasing an additional 147 shares in the last quarter. Quadrant Capital Group LLC increased its position in Corcept Therapeutics by 1.3% during the third quarter. Quadrant Capital Group LLC now owns 14,007 shares of the biotechnology company’s stock worth $1,650,000 after buying an additional 178 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its position in Corcept Therapeutics by 1.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 10,617 shares of the biotechnology company’s stock worth $923,000 after buying an additional 184 shares during the last quarter. State of Wyoming raised its holdings in Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 186 shares in the last quarter. Finally, Wedmont Private Capital raised its holdings in Corcept Therapeutics by 6.1% during the third quarter. Wedmont Private Capital now owns 3,329 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 190 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.
Corcept Therapeutics News Summary
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $165 price target, while projecting substantial longer-term earnings growth, including $6.76 per share in FY2028 and $12.92 in FY2030. HC Wainwright recommendations
- Negative Sentiment: HC Wainwright lowered EPS estimates across several upcoming quarters and years: FY2026 to $2.05 from $2.15 and FY2027 to $3.39 from $3.95, with cuts also to its Q4 2026 and 2027 quarterly forecasts. These downward revisions may temper expectations despite the analyst’s bullish rating. HC Wainwright recommendations
- Negative Sentiment: Insiders Roberto Vieira and Sean Maduck sold substantial portions of their holdings in transactions disclosed this week. Insider sales can raise investor concerns, though they do not necessarily reflect the company’s outlook. Insider selling report
Corcept Therapeutics Company Profile
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role.
Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
See Also
- Five stocks we like better than Corcept Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
